140 related articles for article (PubMed ID: 38147655)
1. Cytoplasmic Shotgun Proteomic Points to Key Proteins and Pathways in Temozolomide-Resistant Glioblastoma Multiforme.
Teraiya M; Krokhin O; Chen VC; Perreault H
J Proteome Res; 2024 Jan; 23(1):465-482. PubMed ID: 38147655
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a Novel Temozolomide Resistant Subline of Glioblastoma Multiforme Cells and Comparative Transcriptome Analysis With Parental Cells.
Ha HA; Yang JS; Tsai FJ; Li CW; Cheng YD; Li J; Hour MJ; Chiu YJ
Anticancer Res; 2021 May; 41(5):2333-2347. PubMed ID: 33952458
[TBL] [Abstract][Full Text] [Related]
3. Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
Lin R; Xu Y; Xie S; Zhang Y; Wang H; Yi GZ; Huang G; Ni B; Song H; Wang Z; Qi ST; Liu Y
J Neurooncol; 2022 Mar; 157(1):15-26. PubMed ID: 35187626
[TBL] [Abstract][Full Text] [Related]
4. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Li D; Yan J; Li K; Yang Q; Bian L; Lin B; Liu X; Xi Z
PeerJ; 2023; 11():e16426. PubMed ID: 38054015
[TBL] [Abstract][Full Text] [Related]
6. WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme.
Ma Z; Cai S; Xiong Q; Liu W; Xia H; Zhu Z; Huang Z; Yan X; Wang Q
Apoptosis; 2022 Feb; 27(1-2):80-89. PubMed ID: 35037107
[TBL] [Abstract][Full Text] [Related]
7. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
9. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
11. Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis.
Qu S; Qi S; Zhang H; Li Z; Wang K; Zhu T; Ye R; Zhang W; Huang G; Yi GZ
J Exp Clin Cancer Res; 2023 Oct; 42(1):285. PubMed ID: 37891669
[TBL] [Abstract][Full Text] [Related]
12. Lnc-TALC promotes O
Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation.
Pak O; Zaitsev S; Shevchenko V; Sharma A; Sharma HS; Bryukhovetskiy I
Prog Brain Res; 2021; 266():195-209. PubMed ID: 34689859
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation.
Jatyan R; Sahel DK; Singh P; Sakhuja R; Mittal A; Chitkara D
J Control Release; 2023 Jul; 359():161-174. PubMed ID: 37182806
[TBL] [Abstract][Full Text] [Related]
16. p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme.
Meng J; Qian W; Yang Z; Gong L; Xu D; Huang H; Jiang X; Pu Z; Yin Y; Zou J
BMC Cancer; 2024 Mar; 24(1):317. PubMed ID: 38454344
[TBL] [Abstract][Full Text] [Related]
17. The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1.
Wang S; Chen C; Li J; Xu X; Chen W; Li F
J Neurol Sci; 2020 Jul; 414():116837. PubMed ID: 32334273
[TBL] [Abstract][Full Text] [Related]
18. Kinome-Wide Synthetic Lethal Screen Identifies PANK4 as a Modulator of Temozolomide Resistance in Glioblastoma.
Vella V; Ditsiou A; Chalari A; Eravci M; Wooller SK; Gagliano T; Bani C; Kerschbamer E; Karakostas C; Xu B; Zhang Y; Pearl FMG; Lopez G; Peng L; Stebbing J; Klinakis A; Giamas G
Adv Sci (Weinh); 2024 Apr; 11(15):e2306027. PubMed ID: 38353396
[TBL] [Abstract][Full Text] [Related]
19. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
20. TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
Yu J; Gao G; Wei X; Wang Y
BMC Cancer; 2022 Jul; 22(1):786. PubMed ID: 35850753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
